Due to limited treatment options the prognosis of patients with advanced hepatocellular cancer (HCC) has remained poor. To investigate an alternative therapeutic approach, we examined the feasibility of radioiodine therapy of HCC following human sodium iodide symporter (NIS) gene transfer using a mouse a-fetoprotein (AFP) promoter construct to target NIS expression to HCC cells. For this purpose, the murine Hepa 1-6 and the human HepG2 hepatoma cell lines were stably transfected with NIS cDNA under the control of the tumor-specific AFP promoter. The stably transfected Hepa 1-6 cell line showed a 10-fold increase in iodide accumulation, while HepG2 cells accumulated 125 I approximately 60-fold. Tumor-specific NIS expression was confirmed on mRNA level by northern blot analysis, and on protein level by immunostaining, that revealed primarily membrane-associated NIS-specific immunoreactivity.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common solid cancer worldwide with an increasing incidence in the Western world. 1 In most patients the development of HCC is associated with cirrhosis resulting from hepatitis B or C virus infection, as well as alcoholic liver disease. 2 Due to limited response to conventional chemo-or radiotherapy, surgery, including partial hepatectomy or liver transplantation, is the only potentially curative therapy that is currently available for patients with resectable disease. Despite the development of various alternative therapeutic options, including cryosurgery, percutaneous ethanol injection, radiofrequency thermal ablation and chemoembolization, the prognosis of patients suffering from advanced HCC has remained poor. Therefore, the development of new therapeutic strategies, including gene therapy, is urgently needed to improve the management of these patients.
Gene therapy for HCC represents a new technology that, more than any currently available therapy, takes direct advantage of our new understanding of tumor carcinogenesis at the molecular level. A variety of gene therapy strategies have been examined for HCC in the recent years, such as immunomodulatory gene therapy including cytokine gene transfer, cytoreductive gene therapy using the herpes simplex virus thymidine kinase/ganciclovir system and the cytosine deaminase/ 5-fluorocytosine system, antiangiogenic gene therapy, corrective gene therapy aiming at restoration of p53 expression, as well as oncolytic viral therapy. 3 However, none of these therapeutic approaches has reached the clinical arena yet.
In contrast to HCC, a well established and highly effective standard therapy exists for follicular-cell derived thyroid cancer taking advantage of endogenous expression of the sodium iodide symporter (NIS) that allows the application of radioactive iodine. 4 NIS, an intrinsic transmembrane glycoprotein with 13 putative transmembrane domains, mediates the active uptake of one iodide ion along with two sodium ions across the basolateral membrane of benign and malignant thyroidal cells, and is competitively inhibited by perchlorate. 5, 6 NIS is therefore not only responsible for the capacity of the thyroid gland to concentrate iodide-the first step in the process of thyroid hormone synthesis-but also represents the molecular basis for diagnostic and therapeutic application of radioiodine in the treatment of thyroid cancer resulting in an excellent prognosis, even in advanced metastatic disease. 7, 8 Based upon the highly effective application of radioiodine that has been used for over 60 years in the management of thyroid cancer, cloning and characterization of the NIS gene 5, 6, 9 has paved the way for the development of a novel radioisotope concentrator gene therapy strategy aiming at targeted NIS expression in thyroidal and nonthyroidal cancer cells making them susceptible to therapeutic destruction by the b-energy emitted by 131 I. 10 In order to achieve tumor selectivity with maximal tumor-specific cytotoxicity and minimal side effects in healthy organs, functional NIS gene expression can be transcriptionally targeted by the application of tissue-or tumor-specific promoters. 11 In earlier studies, we used the prostate-specific antigen (PSA) and probasin promoters to target functional NIS expression to prostate cancer cells, and were able to induce high levels of prostatespecific iodide accumulation that allowed a significant therapeutic effect of 131 I in vitro and in vivo. [12] [13] [14] These data clearly showed the gene therapy and oncology communities for the first time, that NIS gene delivery into nonthyroidal tumor cells is capable of inducing accumulation of therapeutically effective radioiodine doses, and might therefore represent an effective and potentially curative innovative therapy for extrathyroidal tumors.
The current study was developed as a result of the successful application of targeted NIS gene transfer in the prostate cancer model, with the aim of extending this promising novel technique to other tumor types, particularly HCC. We therefore examined the feasibility of radioiodine therapy following human NIS gene transfer in murine and human hepatoma cell lines and used the tumor-specific a-fetoprotein (AFP) promoter to transcriptionally target NIS expression to HCC cells.
Results

Iodide uptake studies in vitro
Iodide uptake was measured in transiently and stably transfected murine Hepa 1-6 and human HepG2 cells, as well as control cancer cell lines LNCaP and MCF-7 following liposome-mediated transfection with AFP/ NIS-pGL3 or the control vector (AFP-pGL3). To specifically block NIS-mediated iodide uptake potassiumperchlorate (KClO 4 ), a competitive inhibitor of NIS, was added to the cells. Hepa 1-6 and HepG2 cells transiently transfected with AFP/NIS-pGL3 showed a four-to fivefold increase in perchlorate-sensitive 125 I accumulation (Figure 1a) , whereas control cancer cell lines without endogenous AFP expression (LNCaP and MCF-7) revealed no perchlorate-sensitive iodide uptake (Figure 1b) . Following stable transfection with AFP/NISpGL3, the Hepa 1-6 cell line Hepa AN-1 concentrated 125 I about 10-fold, and the HepG2 cell line HepG2 AN-1 showed a 60-fold increase in iodide accumulation, whereas no perchlorate-sensitive iodide uptake above background level was observed in cells transfected with . As shown in Figure 2b , no significant organification of accumulated iodide was detected in both cell lines.
Northern blot analysis
Human NIS mRNA expression was examined by high-stringency northern blot analysis using a [a-32P]-labeled hNIS-specific cDNA probe ( Figure 3 
Immunocytochemical staining
Immunofluorescence analysis, using a mouse monoclonal hNIS-specific antibody, showed strong, almost exclusively membrane-associated NIS-specific immunoreactivity in HepG2 cells ( I, whereas 95% (3.5 h)/86% (7 h) of the NIS-negative control HepG2 A-1 cells survived the treatment (Figures 5a and b) . These data indicate that a sufficient high radiation dose was achieved in murine and human hepatoma cells following tumor-specific hNIS gene transfer, to result in selective cell killing at a dose that spared NIS-negative control cells.
Iodide uptake studies in vivo
Three to four weeks after s.c. injection of HepG2 cells, when tumors had reached a tumor size of B1 cm in diameter, 18.5 MBq (500 mCi) 123 I were injected i.p. (n ¼ 5), and radioiodine uptake was determined using a gamma camera. In contrast to HepG2 A-1 tumors (left flank), which showed no radioiodine uptake, HepG2 (Figure 7) . While all the mice in the therapy group (n ¼ 9) could be followed for the 6-week observation period, all of the six mice in each control group (HepG2 AN-1 tumors injected with saline; HepG2 A-1 tumors injected with 131 I) had to be killed before completion of the 6-week observation period (between weeks 2 and 4) due to excessive tumor growth (tumor weight exceeded 10% of body weight). None of the mice showed adverse effects of radionuclide treatment.
Discussion
Based on the extensive experience with diagnostic and therapeutic application of radioiodine in the treatment of thyroid cancer due to native NIS expression in thyroid follicular cells, cloning of the NIS gene in 1996 has provided us with a powerful new diagnostic and therapeutic gene, that allowed the development of a promising cytoreductive gene therapy strategy based on NIS gene transfer in extrathyroidal tumors followed by 131 I application. [5] [6] [7] 9, 10 To protect the thyroid gland, thyroid hormone pretreatment can be used to suppress thyroidal 131 I uptake, that is known to be exquisitely thyroid-stimulating hormone (TSH)-regulated. Even if thyroidal radioiodine uptake would cause damage to the thyroid gland, patients could easily and inexpensively be managed by routine thyroid hormone replacement therapy. 7 Using various gene delivery techniques, including electroporation, liposomes and viral vectors, radioiodine accumulation was induced in vitro and in vivo in a variety of cancer cell lines by NIS gene delivery. 7, 8, 10 These studies demonstrated that, in contrast to other therapeutic genes, NIS is associated with a number of significant advantages: its function as a diagnostic gene allows noninvasive radioiodine imaging to confirm and localize functional NIS expression before proceeding to the application of a therapeutic 
15,16
As one of the first groups to investigate the efficacy of NIS gene therapy in nonthyroidal tumors we chose prostate cancer as initial tumor model and used the PSA promoter to achieve prostate-specific iodide accumulation. 12, 13, 17 In further studies, we were able to confirm these data by the successful application of other tumorspecific promoters, such as the carcinoembryonic antigen (CEA) promoter and the calcitonin promoter, to induce tumor-specific iodide accumulation in colon and medullary thyroid cancer, respectively. [18] [19] [20] To further extend this novel cytoreductive radioisotope concentrator gene therapy strategy to other tumor types, in the current study we chose HCC as another important and distinct tumor model to explore the potential of NIS as a novel therapeutic gene. In order to achieve tumor specificity, we applied the AFP promoter to transcriptionally target NIS gene transfer to HCC cells thereby minimizing toxicity in normal liver cells.
AFP is a 70 000-Dalton protein that is synthesized in the yolk sac and liver of mammals during embryonic development. After birth, the rate of hepatic AFP synthesis decreases to approximately 0.01% of the AFP level in fetal liver, and is reinitiated only in neoplastic transformation or injury to the liver, and in teratocarcinomas. 21 Due to its tumor-specific regulation, AFP is widely used as highly specific tumor marker for HCC and teratocarcinomas, and the AFP promoter therefore represents an ideal means for HCC-specific transcriptional targeting of therapeutic genes. AFP promoter constructs have been applied in a variety of studies and have been demonstrated to effectively target reporter or therapeutic genes to HCC cells, while avoiding toxicity to normal liver cells. [22] [23] [24] [25] Expression of AFP is regulated by four distinct regulatory elements, including the proximal promoter and three enhancer domains (enhancers I, II, III). In our study, to target NIS gene transfer to hepatoma cells we applied a 2666 bp mouse AFP promoter construct consisting of the basal promoter and enhancer I element, that are known to provide maximal tissue specificity and promoter activity. 26 HCC specificity of functional NIS expression was evidenced by lack of iodide uptake activity in control cancer cell lines (breast and prostate cancer cells). Murine and human HCC cells stably expressing hNIS under the control of the AFP promoter concentrated 125 I approximately 10-and 60-fold, respectively. The difference of the iodide accumulating capacity between the murine HCC cell line Hepa 1-6 and the human HCC cell line HepG2 after AFP promoter-mediated NIS gene transfer seems to be the result of enhanced membrane targeting of the NIS protein in the HepG2 cell line. Immunocytochemistry showed very strong and almost exclusively membraneassociated NIS-specific immunoreactivity in HepG2 cells stably expressing hNIS under the control of the AFP promoter, whereas NIS-specific immunoreactivity appeared to be significantly less prominent and more diffusely localized in the Hepa 1-6 cell line. The importance of correct post-transcriptional targeting of NIS to the cell membrane to gain full functional activity has been highlighted in many studies. [27] [28] [29] [30] [31] [32] [33] Further studies exploring the exact post-transcriptional mechanisms responsible for proper membrane targeting of NIS in thyroidal and nonthyroidal cells could provide very useful means to increase the efficacy of NIS gene therapy. Iodide efflux out of NIS-transfected HCC cells was quite rapid in vitro, but comparable to the efflux kinetics observed in LNCaP cells stably expressing NIS under the control of the PSA promoter in one of our earlier studies, probably resulting from the lack of iodide organification. 12, 13 Nevertheless, the amount of accumulated 131 I has been demonstrated to be sufficiently high to selectively kill NIS-transfected HCC cells in a clonogenic assay.
In the thyroid gland thyroid peroxidase (TPO)-catalyzed oxidation and incorporation of iodide into tyrosyl residues along the thyroglobulin backbone, a process called iodide organification, increases the retention time of accumulated iodide in the thyroid gland. One major argument that has frequently been raised against the feasibility of NIS gene therapy for extrathyroidal tumors is the general assumption that organification of trapped iodide is a crucial prerequisite for effective radioiodine therapy. However, while no data exist to support this hypothesis, it has been shown that I NIS expressing HepG2 xenotransplants showed an almost complete tumor growth arrest with survival of all mice without major side effects, while most of the mice in the control group had to be killed after 2-4 weeks already due to rapid tumor growth in an exponential manner.
Because the ultimate goal of this project is to establish a novel therapeutic approach for metastatic HCC, we have also begun to develop adenoviral vectors carrying the NIS gene linked to the AFP promoter aiming at tumor-specific in vivo NIS gene delivery as a next crucial step toward clinical application. The possibility of local virus application via the hepatic artery maximizes regional toxicity with minimal systemic toxicity, still allowing to reach disseminated HCC tumors throughout the liver. At the same time transcriptional tumor targeting by application of the AFP promoter allows to restrict NIS expression to tumor cells to avoid toxicity to normal hepatocytes. The proof of principle of NIS gene therapy in liver cancer has already been reported by Faivre et al., 37 who applied an adenovirus carrying rat NIS under the control of the unspecific CMV promoter intratumorally or via the portal vein and demonstrated strong tumor growth inhibition up to complete tumor regression after application of 131 I in a hepatocarcinoma rat model. In a recent study, Chen et al. 38 performed stable transfection of rat Morris hepatoma cells using a retrovirus carrying the hNIS cDNA under the control of the liver-specific albumin promoter and demonstrated significant iodide accumulation in xenografts in rats that allowed stop of tumor growth. However, application of the liver-specific albumin promoter implies the problem of substantial toxicity to normal hepatocytes, which in our opinion significantly impairs the feasibility of this approach. As in contrast to prostate or thyroid gland, liver is not a 'dispensable' organ, tumor-specific targeting of therapeutic genes has to be one of the major aims of gene therapeutic applications for HCC to avoid liver failure. Therefore, we believe that the AFP promoter, a well-established tumor-specific promoter, as used in our study, is a very promising and ideal tool to transcriptionally target the NIS gene to HCC cells.
In conclusion, a therapeutic effect of 131 I has been demonstrated in HCC cells after induction of tumorspecific iodide accumulation by AFP promoter-driven NIS expression in vitro and in a HCC xenotransplant model in nude mice in vivo. Provided that further studies aiming at systemic in vivo gene delivery will confirm therapeutic efficacy of AFP promoter-targeted NIS gene therapy in the in vivo situation, these data clearly demonstrate the potential of NIS as a novel therapeutic gene allowing targeted radioiodine therapy of HCC.
Materials and methods
Cell culture
The murine and human HCC cell lines Hepa 1-6 and HepG2 were grown in DMEM, the human breast cancer cell line MCF-7 in MEM and the human prostate cancer cell line LNCaP in RPMI medium (all media obtained from Invitrogen Life Technologies Inc., Karlsruhe, Germany). Each medium was supplemented with 10% fetal bovine serum (PAA, Colbe, Germany), L-glutamine and penicillin/streptomycin. Cells were maintained at 37 1C and 5% CO 2 in an incubator with 95% humidity. The culture medium was replaced every second day and cells were passaged at 85% confluency.
Plasmid construct
The full-length NIS cDNA was removed from the pcDNA3 expression vector (kindly provided by Dr SM Jhiang, Ohio State University, Columbus, OH, USA) by restriction digestion using XbaI and HindIII, agarose gel purified and ligated into the promoterless expression vector pGL3-Basic (Promega, Mannheim, Germany) resulting in NIS-pGL3. A murine AFP promoter/ enhancer fragment consisting of the basal promoter and the enhancer element I (2666 bp) was PCR-amplified including restriction enzyme cleavage sites (NheI and MluI) and cloned into the NIS-pGL3 vector. The resulting plasmid construct containing full-length NIS cDNA coupled to the AFP promoter (AFP/NIS-pGL3) was agarose-gel purified and confirmed by DNA sequencing. A control vector was designed containing the AFP promoter/enhancer fragment without the NIS cDNA (AFP-pGL3).
Transient transfection
The murine HCC cell line Hepa 1-6, the human hepatoma cell line HepG2 and control cell lines MCF-7 and LNCaP were used in transient transfection experiments. Prior to transfections, cells were grown to 50-60% confluency and switched to serum-free media 1 h before transfection with AFP/NIS-pGL3 or the control vector AFP-pGL3 using LipofectAMINE Plus reagent (Life Technologies) according to manufacturer's recommendations. Following transfection, cells were incubated for 48 h in growth medium. All groups of cells were prepared in triplicate for transfections, which were performed at least three times.
Stable transfection
Hepa 1-6 and HepG2 cells were co-transfected with AFP/NIS-pGL3 or the control vector AFP-pGL3, respecSodium iodide symporter gene therapy in liver cancer MJ Willhauck et al tively, and a plasmid containing a puromycin resistance cassette (pBabePuro) (1/20 of the applied concentration of AFP/NIS-pGL3 or AFP-pGL3) using LipofectAMINE Plus reagent under serum-free conditions as described above. Selection of transfected cells were maintained with 3 mg ml À1 (Hepa 1-6) and 1.25 mg ml À1 (HepG2) puromycin (Sigma, Taufkirchen, Germany) in DMEM medium containing 10% FCS for approximately 2 weeks from the day after transfection. Surviving cell clones were isolated and subjected to screening for iodide uptake activity. Five stably transfected cell lines of each cell type (Hepa AN-1 to -5 and HepG2 AN-1 to -5 (AFP/ NIS-pGL3)) that showed the highest levels of iodide accumulation among approximately 50 screened colonies were obtained. In addition five stably transfected control cell lines for each cell type were obtained (Hepa A-1 to -5 and HepG2 A-1 to -5 (AFP-pGL3)).
Iodide uptake studies in vitro
Uptake of 125 I by transfected murine and human hepatoma cells was determined at steady-state conditions as described by Weiss et al. 39 In brief, cells were plated on six-well plates (3 Â 10 5 cells per well), and following transfection, iodide uptake studies were performed in HBSS supplemented with 10 mM NaI, 3.7 MBq (0.1 mCi) Na 125 I ml
À1
, and 10 mM HEPES (pH 7.3). A 100 mM concentration of KClO 4 (a competitive inhibitor of NIS) was added to control wells. Following incubation for 1 h, trapped iodide was removed from cells by a 20 min incubation in 1 N NaOH and measured by g-counting.
Iodide efflux studies in vitro Efflux of 125 I was determined as described by Weiss et al. 39 In brief, cells were plated on six-well plates (3 Â 10 5 cells per well) and incubated with HBSS supplemented with 10 mM NaI, 3.7 MBq (0.1 mCi) Na 125 I ml
and 10 mM HEPES (pH 7.3) at 37 1C for 1 h. A 100 mM concentration of KClO 4 was added to control wells prior to application of 125 I. Medium was then replaced every 2-5 min with fresh HBSS. The content of 125 I in the collected supernatant was measured by g-counting. After the last time point, trapped 125 I was removed from cells by a 20 min incubation in 1 N NaOH and measured by g-counting.
Measurement of iodide organification
Cells grown in six-well plates were incubated for 1 h at 37 1C with HBSS supplemented with 10 mM NaI, 3.7 MBq (0.1 mCi) Na 125 I ml À1 and 10 mM HEPES (pH 7.3). Contents of organified iodide in the cells were determined by TCA precipitation as described by Urabe et al. 40 
RNA preparation and northern blot analysis
Total RNA was isolated using the RNeasy Mini kit according to the maufacturer's recommendations (Qiagen, Hilden, Germany). Aliquots (20 mg) of RNA were electrophoresed on a 1% agarose gel containing 2 M formaldehyde and transferred overnight in 20 Â saline sodium citrate (SSC) to a positively charged nylon membrane (Amersham, Freiburg, Germany). The human NIS cDNA-fragment (nucleotides 1184-1667) was radiolabeled with [a-32P] dCTP by random priming (Perkin Elmer, Cologne, Germany), and used as a hybridization probe. Blots were prehybridized at 68 1C in hybridization solution (Express Hyb solution, Clontech Laboratories Inc., Heidelberg, Germany) for 30 min, followed by hybridization at 68 1C for 1 h. Blots were then rinsed four times in 2 Â SSC/0.05% SDS at room temperature for 10 min and twice in 0.1 Â SSC/0.1% SDS at 50 1C for 20 min, respectively. Exposures were made at À80 1C for 48 h using Biomax MS films (Sigma). To strip off the NIS cDNA probe, blots were treated in 0.5% SDS at 95 1C for 10 min and reprobed with a human b-actin cDNA probe to monitor RNA integrity and quantity.
Immunocytochemical staining
Immunocytochemical staining was performed using an indirect immunofluorescence technique. Hepa 1-6 and HepG2 cells were plated on slides and grown as monolayers to 60% confluency. Cells were washed and fixed for 5 min in 80% methanol at 4 1C and 2 min in acetone at À20 1C, followed by rehydration in 1 Â PBS. Cells were then incubated with a mouse monoclonal antibody directed against amino acid residues 468-643 of human NIS 28 at a dilution of 1:3000 in 4% BSA/PBS for 2 h at room temperature. After washing in 1 Â PBS (3 Â 10 min) slides were incubated with donkey antimouse CY3-labeled secondary antibody along with 10 mg ml À1 DAPI nuclear stain at RT for 30 min. Prior to embedding in Permafluor (Immunotech, Marseille, France) slides were washed again (3 Â 5 min) in 1 Â PBS. Parallel monolayers with the primary and secondary antibodies replaced in turn by PBS and isotype-matched nonimmune IgGs were examined to assure specificity and to exclude crossreactivities between the antibodies and conjugates used. Stained sections were examined at an Olympus AX-70 microscope equipped with epifluorescence optics and recorded with a digital camera (FView 12, Soft Imaging System (SIS), Muenster, Germany) applying AnalySIS Pro 6.0-software.
In vitro clonogenic assay
The in vitro clonogenic assay was performed as described by Mandell et al. 41 In brief, NIS-and mock-transfected cells were grown in 75 cm 2 flasks, washed with HBSS and incubated for 3.5 h or 7 h with 10 ml of 2.96 MBq (80 mCi) ml À1 Na 131 I in HBSS supplemented with 10 mM NaI and 10 mM HEPES at pH 7.3. Following incubation with radioiodine, cells were washed with HBSS, trypsinized using 0.05% trypsin-EDTA, and plated at cell densities of 50, 100, 200, 500, 1000, 2000 and 3000 cells per well (12 wells each) in 12-well plates. Two weeks later, after colony development, cells were fixed with methanol, stained with crystal violet and colonies containing more than 50 cells were counted. Parallel experiments were performed for each treatment using HBSS without 131 I, and all values were adjusted for plating efficiency. The percentage of survival represents the percentage of cell colonies after 131 I treatment, compared with mock treatment with HBSS.
Iodide uptake studies in vivo
Xenotransplants derived from HepG2 AN-1 (right flank) and A-1 (left flank) were established in female NMRI nu/nu mice (Harlan Winkelmann, Borchen, Germany) by s.c. injection of 1 Â 10 6 cells suspended in 0.1 ml of DMEM. Nude mice were maintained under specific pathogen-free conditions with access to mouse chow and Sodium iodide symporter gene therapy in liver cancer MJ Willhauck et al water ad libitum. The experimental protocol was approved by the regional governmental commission for animal protection (Regierung von Oberbayern). Two weeks after s.c. injection of transfected HepG2 cells, when tumors had reached B0.8 cm in diameter, mice were switched to a low-iodine diet and received T4 supplementation (5 mg l À1 ) in their drinking water for 2 weeks to maximize radioiodine uptake in the tumor and reduce uptake by the thyroid gland. After i.p. injection of 18.5 MBq (500 mCi) 123 I, radioiodine imaging was performed using a gamma camera equipped with a VXHR collimator (Forte, ADAC Laboratories, Milpitas, CA, USA). Regions of uptake have been quantified and expressed as a fraction of the total amount of the applied radionuclide. Iodine retention time within the tumor was determined by serial scanning after radionuclide injection, and dosimetric calculations were performed (OLINDA.EXM Software).
Radioiodine therapy study in vivo
Two groups of mice harboring HepG2 A-1 tumors (n ¼ 6) or HepG2 AN-1 tumors (n ¼ 9) were administered 55.5 MBq (1.5 mCi) 131 I by a single i.p. injection after 2-3 weeks of tumor growth, while a control group harboring HepG2 AN-1 tumors (n ¼ 6) were injected with saline only. Tumors were measured before administration of 131 I and weekly thereafter for 6 weeks. Tumor volume was estimated using the formula: tumor volume ¼ length Â width Â height Â 0.52. Mice were killed before the end of the 6-week observation period, when tumor weight exceeded 10% of body weight, when tumors started to necrotize, in case of weight loss of more than 10% or impairment of drinking and eating behavior of mice. Statistical significance was tested using Student's t-test.
Statistical methods
All experiments were performed in triplicates. For the clonogenic assay, 12 wells were evaluated for each condition and cell density. Results are presented as means ± s.e.m. of triplicates. Statistical significance was tested using Student's t-test. Results shown are representative of three experiments performed under the same conditions.
